References
- Antonelli-IncalziRImperialeCBelliaV2003Do GOLD stages of COPD severity really correspond to differences in health status?Eur Respir J22444914516133
- BurgeSWedzichaJA2003COPD exacerbations: definitions and classificationsEur Respir J21Suppl 4146s53s
- CalverleyPMBoonsawatWCsekeZ2003Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J229121914680078
- CalverleyPPauwelsRVestboJ2003Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet36144956
- CrapoROMorrisAHGardnerRM1981Reference spirometric values using techniques and equpment that meet ATS recommendationsAm Rev Respir Dis123659647271065
- CrapoROMorrisAH1981Standardized single-breath normal values for carbon monoxide diffusing capacityAm Rev Respir Dis12318597235357
- CrapoROMorrisAHClaytonPD1982Lung volumes in healthy nonsmoking adultsBull Europ Physiopathol Respir1841925
- Dal NegroRWPomariCTognellaS2003aSalmeterol and fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with theophyllinePulm Pharmacol Ther16241612850128
- Dal NegroRWRossiACerveriI2003bThe burden of COPD in Italy: results from the Confronting COPD surveyRespir Med97Suppl CS43S5012647942
- De MarcoRAccordiniSCerveriI2004An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stagesThorax59120514760151
- Domingo-SalvanyALamarcaRFerrerM2002Health-related quality of life and mortality in male patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med166680512204865
- DrummondMFO’BrienBStoddartGL1997Methods for the economic evaluation of health care programmes2nd edOxfordOxford University Press
- FletcherCMPetoRTinkerCM1976The natural history of chronic bronchitis and emphysemaOxfordOxford University Press
- GagnonYMLevyARSpencerMD2005Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationRespir Med9915344516291076
- [GOLD] Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated. 2004Executive summary. Based on April 1998 NHLBI/WHO Workshop.
- HankinsonJLOdencrantzJRFedanKB1999Spirometric reference values from a sample of the general U.S. PopulationAm J Respir Crit Care Med159179879872837
- [ISTAT] Italian National Statistic Institute2001Indagine Multiscopo sulle famiglie: condizioni di salute e ricorso ai servizi sanitari anno 1999–2000RomeISTAT
- [ISTAT] Italian National Statistic Institute2003Annuario statistico italiano 2003RomeISTAT
- LofdahlCGEricssonASvenssonK2005Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alonePharmacoeconomics233657515853436
- LucioniCDonnerCFDe BenedettoF2005I costi della broncopneumopatia cronica ostruttiva: la fase prospettica dello studio ICE (Italian Costs for Exacerbations in COPD)Pharmacoeconomics. Italian research articles711934
- PriceDTinkelmanDGNordykeRJ2004Severity distribution of COPD in primary care [abstract]Proceedings of the European Respiratory Society CongressAbstract ERS4L1_2562.
- StangPLydickESilbermanC2000The prevalence of COPD. Using smoking rates to estimate disease frequency in the general populationChest117354s9s10843976
- SpencerMBriggsAHGrossmanRF2005Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseasePharmacoeconomics236193715960557
- SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide/formoterol in the management of chronic ostructive pulmonary diseaseEur Respir J21748112570112
- ViegiGPaolittiPPredilettoR1988Prevalence of respiratory symptoms in an unpolluted area of Northern ItalyEur Respir JI311183260872
- ViegiGScognamiglioABaldacciS2001Epidemiology of chronic obstructive pulmonary diseaseRespiration 200168419
- [WHO] World Health Organization2000World health reportGenevaWHO